Changing paradigm of immunooncology in advanced kidney cancer: nivolumab and ipilimumab combination in the first line therapy
https://doi.org/10.17650/1726-9776-2019-15-1-125-130
Abstract
Until now selection of the 1st line therapy for advanced clear-cell renal cell carcinoma was determined by patients distribution into favorable/ intermediate or poor prognosis groups. In the favorable/ intermediate prognostic groups agents of choice included antiangiogenic substances such as bevacizumab (in combination with interferon-alpha), sunitinib, andpazopanib, which had demonstrated only progression-free survival benefit comparing with interferon-alpha in registration studies; in the poor prognosis group the only treatment option was mammalian target of rapamycin inhibitor temsirolimus which had improved overall survival comparing with interferon-alpha. However about 75 % of advanced renal cell carcinoma patients have intermediate or poor prognosis. Only 2 randomized trials investigated systemic therapy in this cohort of patients, CABOSUN and CheckMate 214. The results of the randomized phase III study CheckMate 214 have demonstrated a significant advantage of overall survival and objective response rate in previously untreated patients of intermediate/poor prognostic groups who were randomizedfor combined immunotherapy with nivolumab and ipilimumab comparing with sunitinib independently of PD-L1 expression level. Owing to the achieved data combined immunotherapy became a new standard of the first-line therapy in advanced renal-cell carcinoma patients with intermediate and poor prognosis.
About the Authors
V. B. Matveev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: no conflict of interest
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: no conflict of interest
M. I. Volkova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Competing Interests: no conflict of interest
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
Competing Interests: no conflict of interest
A. S. Olshanskaya
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia ; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests: no conflict of interest
Russian Federation
Department of Oncology
1 Ostrovityanova St., Moscow 117997
Competing Interests: no conflict of interest
References
1. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol 2016;17:883-95.
2. Cella, et al. Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial. Lancet Oncol. 2019 Feb; 20(2): 297-310.
3. Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015;21:1071-7.
4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
5. Escudier B, Szczylik C, Hutson TE, et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009;27: 1280-9.
6. Escudier, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Feb 21. pii: mdz056. doi: 10.1093/annonc/mdz056. [Epub ahead of print].
7. Hammers HJ, Plimack ER, Infante JR, et al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J Clin Oncol 2017;35:3851-8.
8. Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced nonsmall-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41.
9. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016;17:1558-68.
10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
11. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
12. Mc Dermott, et al.,Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214 Journal of Clinical Oncology 37, no. 7_suppl (March 1 2019) 564-564.Published online February 26, 2019.
13. Motzer et al. N Engl J Med 2018.
14. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803-13.
15. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
16. Motzer, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5; 378(14): 1277-1290.
17. Rothrock N.E., Jensen S.E., Beaumont J., Abernethy A., Jacobsen P.B., Syrjala K.L., Cella D. National Comprehensive Cancer Network Functional Assessment of Cancer Therapy (FACT) –Kidney Symptom Index 19 (NCCN-FACT FKSI-19), 2013 Jul-Aug; 16 (5):789-96.
18. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer, version 3.2019.
19. Opdivo Prescribing Information. Opdivo U.S. Product Information. Last updated: January 27, 2017. Princeton, NJ: Bristol-Myers Squibb Company.
20. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008; 26:5422-8.
21. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010;28:1061-8.
22. Tannir , et al. Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214, Journal of Clinical Oncology 37, no. 7_suppl (March 1 2019) 581-581.Published online February 26, 2019.
23. Tannir, et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 37, 2019 (suppl.7S; abstr.547).
24. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369:122-33.
25. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007;30:825-30.
26. Yervoy (ipilimumab) injection for intravenous use (prescribing information). Princeton, NJ: Bristol-Myers Squibb, 2017.
Review
For citations:
Matveev V.B., Volkova M.I., Olshanskaya A.S. Changing paradigm of immunooncology in advanced kidney cancer: nivolumab and ipilimumab combination in the first line therapy. Cancer Urology. 2019;15(1):125-130. (In Russ.) https://doi.org/10.17650/1726-9776-2019-15-1-125-130
Views:
1231
Email this article 